 The European Commission has granted conditional marketing authorization for Karyopharm Therapeutics Incs NASDAQ: KPTI Nexpovio selinexor for multiple myeloma. The approval covers Nexpovio combined with dexamethasone for multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. 